D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Samath Jamie, Executive Vice President and Chief Financial Officer of Intuitive Surgical Inc . (NASDAQ:ISRG), recently executed a series of transactions involving the company’s common stock. According to a Form 4 filing with the Securities and Exchange Commission, Jamie sold shares on February 28, 2025, totaling $106,584. The shares were sold at a price of $566.94 each, close to the current trading price of $566.98. The medical technology giant, now valued at approximately $202 billion, has seen its stock rise over 42% in the past year. According to InvestingPro analysis, the stock currently trades at premium multiples, with a P/E ratio of 87.
In addition to the sale, Jamie also engaged in multiple acquisitions of stock through the exercise of options and restricted stock units. These transactions were completed at no cost, with the acquired shares priced between $208.9 and $290.33.
The transactions took place under a pre-established trading plan compliant with SEC Rule 10b5-1, which is set to expire on May 6, 2025. After these transactions, Jamie holds a total of 7,162 shares of Intuitive Surgical.
In other recent news, Intuitive Surgical reported a strong fourth quarter in 2024, with revenue and earnings per share (EPS) surpassing expectations by 10% and 24%, respectively. The company also projected a 13-16% year-over-year increase in procedure volume for 2025, aligning with its history of setting conservative targets. Analysts from RBC Capital Markets, Piper Sandler, and Bernstein have all maintained positive ratings on Intuitive Surgical, citing the company’s robust financial performance and future growth prospects. Piper Sandler raised its price target to $670, while Bernstein set a target of $700, reflecting confidence in the company’s market position and product pipeline.
Oppenheimer, on the other hand, maintained a Perform rating, expressing caution due to potential market saturation in the U.S. and the pricing of the new da Vinci (EPA:SGEF) 5 system. Meanwhile, Truist Securities increased its price target to $666, highlighting the anticipated mid-year launch of the da Vinci 5 system as a significant growth driver. Intuitive Surgical’s gross margin guidance for 2025 was slightly below some analysts’ estimates, but firms like Piper Sandler expect margins to improve over the mid-term. The company also secured a €290 million distribution agreement in Europe, further expanding its market presence. Overall, Intuitive Surgical’s recent developments indicate a strong performance trajectory, supported by its innovative surgical systems and strategic market expansions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.